

## Special Issue

# Mesothelioma: Diagnosis and Therapy

### Message from the Guest Editor

Malignant mesothelioma is a rare incurable cancer that is predominantly related to asbestos exposure. There have been numerous advances in this field, including innovations in diagnostics, the development of enhanced staging and immunotherapy treatment, and novel evidence regarding surgical treatments and intrapleural therapy. This Special Issue therefore welcomes the submission of articles related to these topics. We are pleased to invite you to contribute to this Special Issue on mesothelioma with original research articles and reviews. The research included in this Special Issue may present updated diagnostic methods, novel treatment options and debates around surgical treatment. I look forward to receiving your contributions.

---

### Guest Editor

Dr. Avinash Aujayeb

1. Respiratory Medicine Department, Northumbria Healthcare NHS Foundation Trust, Cramlington NE22 9EH, UK

2. Department of Respiratory Medicine, North Tyneside General Hospital, North Tyneside, Newcastle NE298NH, UK

---

### Deadline for manuscript submissions

30 November 2025



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/215674](https://mdpi.com/si/215674)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)